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Background: Evidence suggests that cytoglobin (Cygb) may function as a tumor suppressor gene.
Methods: We immunohistochemically evaluated the expression of Cygb, phosphatidylinositol-3 kinase (PI-3K),
phosphorylated (p)-Akt, Interleukin-6 (IL-6), tumor necrosis factor-α (TNFα) and vascular endothelial growth factor
(VEGF) in 88 patients with 41 high-grade gliomas and 47 low-grade gliomas. Intratumoral microvessel density (IMD)
was also determined and associated with clinicopathological factors.
Results: Low expression of Cygb was significantly associated with the higher histological grading and tumor
recurrence. A significant negative correlation emerged between Cygb expression and PI3K, p-Akt, IL-6, TNFα or
VEGF expression. Cygb expression was negatively correlated with IMD. There was a positive correlation between
PI3K, p-Akt, IL-6, TNFα and VEGF expression with IMD.High histologic grade, tumor recurrence, decreased Cygb
expression, increased PI3K expression, increased p-Akt expression and increased VEGF expression correlated with
patients’ overall survival in univariate analysis. However, only histological grading and Cygb expression exhibited a
relationship with survival of patients as independent prognostic factors of glioma by multivariate analysis.
Conclusions: Cygb loss may contribute to tumor recurrence and a worse prognosis in gliomas. Cygb may serve as
an independent predictive factor for prognosis of glioma patients.
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Glioma is the most common brain tumor in adults. Its
ability to evade immune surveillance and impede anti-
tumor responses leads to sustained growth and en-
hanced malignancy [1,2]. Increasing evidence indicates
that cytoglobin (Cygb) and the cytokine influences sev-
eral aspects of gliomas [3-5]. Cygb is the fourth member
of the vertebrate globin family and was identified inde-
pendently by three groups shortly thereafter [6]. The func-
tions of Cygb remain to be elucidated; however, it may
include detoxification of reactive oxygen species (ROS) and* Correspondence: xzy3175@yahoo.com.cn; Guoj_zhang@yahoo.com
1Department of Neurosurgery, Second Affiliated Hospital of Shantou
University Medical College, North Dongxia Rd, Shantou 515041, Guangdong,
China
7The Breast Center, Cancer Hospital of Shantou University Medical College,
Raoping Rd, Shantou 515031, Guangdong, China
Full list of author information is available at the end of the article
© 2013 Xu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orscavenging NO [7,8]. Although the function of Cygb
in vivo remains largely unknown, decreased expression of
Cygb and the hypermethylation of the Cygb promoter has
been reported in patients with tylosis, non–small-cell lung
carcinomas, head and neck cancers, ovarian cancers, and
breast cancers [9-12]. Those results suggest that Cygb may
function as a tumor suppressor gene [13].
Cygb loss has been reported to be associated with in-
creased cancer cell proliferation, elevated extracellular sig-
nal–regulated kinase and Akt activation, overexpression of
interleukin-6 (IL-6) [14]. Deregulated signaling through
phosphatidylinositol-3 kinase (PI-3K)/Akt pathways has
been implicated in the malignant transformation of glial
cells [15]. Akt is known to regulate actin cytoskeleton
reorganization that plays role in tumor cell migration and
invasion [16], and inhibition of Akt prevents glioma cell
growth [17]. IL-6 is implicated as major regulators ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mune response, preferentially activates the signal trans-
ducer and activator of transcription-3 (STAT-3), leading to
dimerization, nuclear translocation and binding to IFN-c
-activated site-like DNA elements [18]. IL-6 cytokine has
been extensively studied in astroglial tumors at the mRNA
[19] and protein level [20,21] and has been proposed as a
determinant of brain tumor progression [22]. It has been
shown in experimental models that development of glio-
blastoma requires the presence of IL-6 [23]. Knowing that
IL-6 functions as a downstream mediator for tumor ne-
crosis factor-α (TNF-α) [24], IL-6 is also recognized as po-
tent regulators of angiogenesis [vascular endothelial
growth factor (VEGF)] [25]. However, in gliomas, few pre-
vious studies have focused on the correlation between
Cygb and VEGF. The relationship between Cygb and pro-
duction of immunosuppressive cytokines (IL-6, TNFα, et
al) by tumor cells in gliomas also needs to be confirmed.
The paucity of prognostic information regarding Cygb ex-
pression and the prognostic role of PI3K/Akt signaling in
gliomas prompted us to undertake the present study.
In the clinical setting, the histological grading is a key
factor for predicting the biological behavior of gliomas
and influencing the choice of therapies, particularly de-
termining the use of adjuvant radiation and specific
chemotherapy protocols [26,27]. However, to our know-
ledge, the exact relationship between histological grading
and Cygb expression in tumor cells of glioma has not
yet been elucidated. In addition, histological grading
makes a contribution toward an estimate of recurrence
in gliomas, while a possible relationship between Cygb
and glioma recurrence remains to be confirmed.
Therefore, the first goal of this study was to determine
Cygb, PI3K, phosphorylated (p)-Akt, IL-6, TNFα and
VEGF expression in gliomas. And the second goal of this
study was to examine the interaction between Cygb-
PI3K/Akt signaling and cytokines (IL-6, TNFα, VEGF),
to assess possible relationships of these molecules with
clinicopathological features and patients’ survival.
Methods
Patient’s description
The study was carried out in patients with histologically
confirmed high and low grade gliomas operated on in
the Department of Neurosurgery of Second Affiliated
Hospital of Shantou University Medical College between
January of 2002 and December of 2011. 88 patients were
selected according to our inclusion criteria, which were
as follows: All patients with intracranial gliomas for
whom archival primary tumor material at diagnosis, age
over 18 years old, no previous history of any tumor, no
administration of antiepileptic drugs or steroids for more
than 3 days, no chemotherapy or radiotherapy received
before surgery. Histological sections of the resectedprimary specimens were reviewed by a senior pathologist
according to the criteria of WHO histological classifica-
tion [28]. All the enrolled patients had received brain
tumor resection. After surgery, the patients with glioblast-
oma multiforme and anaplastic astrocytoma (WHO grade
IV and III) were treated with teniposide (70 mg/m2 /day,
3 consecutive days during each 42-day cycle) for 4-6
cycles. The patients with astrocytoma (WHO grade II)
were treated with teniposide for 1 cycle only after the ini-
tial surgery. The patients with oligodendrogliomas and
oligoastrocytoma underwent PCV chemotherapy [procar-
bazine, methyl-1-(2-chloroethyl)-1-nitrosourea (CCNU),
and vincristine] every 6 weeks (42-day cycles) for 2-5
cycles [29]. In the study, written informed consents were
obtained for all patients, and the study was approved by
the Medical Ethics Committee of the Second Affiliated
Hospital Shantou University Medical College.
Immunohistochemical staining and scoring
Three continual sections of 4-5μm sections were
subjected to immunostaining using a SP Kit (DAKO,
Denmark). Slides were deparaffinized in xylene and
rehydrated in decreasing concentrations of ethanol and
rinsed in phosphate-buffered saline. The slides were in-
cubated with hydrogen peroxide for 20 min following
microwave heating with 10 mM citrate buffer (pH 6.0;
Sigma-Aldrich, Germany) at 2-min intervals for a total
of 10 min. After blocking with normal serum for 30 min,
the slides were incubated with rabbit polyclonal anti-
body. The following antibodies were used: anti-Cygb di-
luted 1:300(bs-0590R, Bioss), anti-PI3K diluted 1:200(bs-
0128R, Bioss), anti-Akt diluted 1:200(bs-0115R, Bioss),
anti-IL-6 diluted 1:300(bs-0781R, Bioss), anti-TNFα di-
luted 1:300(bs-0078R, Bioss), and anti-VEGF diluted
1:200(RAB-0157, Maixin_Bio). In addition, all cases had
been stained CD34 for microvessel counting using anti-
CD34 antibody diluted 1:100(bs-2038R, Bioss). All rabbit
polyclonal antibodies used were provided by Biosyn-
thesis (Beijing, China). The incubation time was 1 h at
room temperature for CD34 and 20 h at 4°C for Cygb,
PI3K, p-Akt, IL-6, TNFα and VEGF. Slides were
detected by SP Kit for 30 min at room temperature and
followed by developing with diaminobenzidine for
visualization. Negative controls included sections where
primary antibody had been substituted by nonimmune
serum.
Cygb, PI3K, p-Akt, IL-6, TNFα and VEGF immunore-
activity was evaluated by light microscopy by two experi-
enced pathologists without knowledge of the clinical
information. If a discrepancy occurred between the
assessments of the two observers, the slides were
reassessed in a combined session without information of
the previous scores. In each section, the percentage of
tumor cells with Cygb, PI3K, p-Akt, IL-6, TNFα and
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cells counted in several randomly chosen high power
fields. In each case, the percentage of tumor cells with
Cygb, PI3K, p-Akt, IL-6, TNFα and VEGF immunoreac-
tivity was the mean value of the 3 continual sections.
High expression of proteins was more than median value
of tumor cells with positive staining, whereas low expres-
sion was less than median value. Intratumoral microvessel
density (IMD) was observed in areas of most intense
neovascularization or hotspots in the tumor by light mi-
croscopy. After the area of the highest neovascularization
was determined, single microvessels were manually
counted on a × 200 field by two independent observers
without knowledge of the patient outcome. Any brown-
stained endothelial cell or cell cluster that was clearly sep-
arated from adjacent microvessels was considered as a
single, countable microvessel, and the IMD value of each
sample was the mean of the independent microvessels
counts by two observers.Statistical analysis
All statistical analysis was carried out by SPSS 17.0 soft-
ware for Windows. In the basic statistical analysis Cygb,
PI3K, p-Akt, IL-6, TNFα and VEGF expressions were
treated as continuous variables to avoid any “data-
driven” categorization. Associations of Cygb, PI3K, p-
Akt, IL-6, TNFα and VEGF expression with clinicopath-
ological characteristics were tested using non-parametric
tests with correction for multiple comparisons (Kruskal–
Wallis ANOVA, Mann–Whitney U-test and Spearman’s
rank correlation coefficient). Correlations among Cygb,
PI3K, p-Akt, IL-6, TNFα and VEGF and microvascular
parameters were tested with Spearman’s correlation co-
efficient. Vascular density was given as the mean ± SD as
indicated. Data were analyzed by one-way ANOVA with
Dunnett’s post hoc test and Turkey’s post hoc test for
multigroup comparisons. The survival curve of patients
was determined by the Kaplan–Meier method and Cox
regression, and statistical evaluation was performed
using the log rank test. All results with a two-sided
p level < 0.05 were considered statistically significant.Results
Patients characteristics
The patients were 51 males and 37 females with median
age of 41 years old (range 18–74). The high grade group
included 15 patients with glioblastoma multiforme
(GBM), (WHO grade IV), 26 patients with anaplastic gli-
omas (AG), (WHO grade III) and 47 patients with low
grade gliomas (LGG), (WHO grade I–II). The followed-
up was made by telephone call or clinic with median of
20 months (3-80 months). 43 disease-specific deaths
were recorded during follow-up.Immunohistochemical assessment of Cygb, PI3K, p-Akt, IL-6,
TNFα and VEGF in gliomas
Cytoplasmic and nucleus surface positive staining for
Cygb, PI3K and p-Akt was observed in tumor cells of
gliomas, no positive staining was shown in tumor cells
of negative controls (Figure 1). Immunostaining signal of
IL-6, TNFα and VEGF was localized in the cytoplasm of
tumor cells (Figure 2) and CD34 was localized in endo-
thelial cells of newly formed vessels. On serial section,
CYGB, PI3K, p-Akt, IL-6, TNFα and VEGF could be
detected in the same area of tumor cells, at least in a
part of them.
Positive staining for Cygb, PI3K, p-Akt, IL-6, TNFα
and VEGF were observed in 10%-86% (median value:
39%), 3%-62% (median value: 20%), 5%-67% (median
value: 21%), 4%-70% (median value: 35%), 3%-67% (me-
dian value: 30%) and 10%-89% (median value: 56%),
respectively. Low expression of Cygb was significantly
associated with the higher histological grading and
tumor recurrence. High expression of PI3K, p-Akt, IL-6,
TNFα and VEGF were significantly associated with the
higher histological grade, and high expression of PI3K,
p-Akt and IL-6 were significantly associated with tumor
recurrence. There was no correlation observed between
Cygb, PI3K, p-Akt, IL-6, TNFα or VEGF expression and
age of patients (Table 1). However, Cygb expression was
significantly higher in female patients.
Correlations between Cygb, PI3K, p-Akt, IL-6, TNFα,and
VEGF immunoreactivity in gliomas
A significant negative correlation emerged between Cygb
expression and PI3K or p-Akt expression (r = -0.728,
p <0.0001 and r = -0.711, p <0.0001 respectively). High
PI3K and p-Akt expression was correlated with high IL-6
(r = 0.302, p = 0.004 and r = 0.328, p = 0.002, respectively)
and TNFα expression (r = 0.278, p = 0.009 and r = 0.308,
p = 0.004, respectively). IL-6 expression levels were
positively associated with TNFα expression (r =0.724,
p = <0.0001). There was significant negative correlation
observed between Cygb expression and IL-6 or TNFα
or VEGF expression (r = -0.370, p <0.0001, r = -0.345,
p = 0.001 and r = -0.378, p < 0.0001 respectively). High
expression of IL-6 and TNFα exhibited a close correl-
ation with high expression of VEGF in the tumor cells
(r = 0.714, p < 0.0001 and r =0.702, p < 0.0001 respect-
ively) (Table 2).
Correlation of Cygb, PI3K, p-Akt, IL-6, TNFα and VEGF
expression with IMD in gliomas
Microvessels in gliomas, specifically stained by anti-
CD34 immunostaining, were observed in all specimens,
and scored as IMD. The mean IMD value was 30/HPF,
but with great individual variation (range 12–56). The
correlation between IMD and proteins expression in
Figure 1 Immunohistochemical staining of Cygb, PI3K and p-Akt in low and high grade of glioma tissues. Negative control (NC) of low
(a) and high (A) grade gliomas showed no positive staining cells. Strong and diffused expression of Cygb was found in low-grade gliomas (b); in
high-grade gliomas, positive staining of Cygb was shown focally and weakly (B). Low-grade gliomas showed low expression of PI3K (c) and p-Akt
(d) positive tumor cells in serial section. High expression of PI3K (C) and p-Akt (D) was shown in high-grade gliomas. (magnification: ×400).
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tively correlated with IMD. There was a positive correl-
ation between PI3K, p-Akt, IL-6, TNFα and VEGF
expression with IMD. The IMD was significantly higher
in tumors with high expression of PI3K, p-Akt, IL-6,
TNFα or VEGF than in tumors with lower protein ex-
pression (Table 2).
Association of Cygb, PI3K, p-Akt, IL-6, TNFα and VEGF
expression with survival of patients with gliomas
The 88 cases were followed up from 3 to 80 months
with a mean period of 20 months, and 43 patients
(48.9%) had died of their tumor during this period. The
mean survival time of patients with high-grade tumors
(WHO III–IV) and low-grade tumors (WHO I–II) were
17.3 ± 1.7 and 60.7 ± 4.2 months, respectively; there was
a statistically significant difference (p <0.01).
Univariate survival analysis (Kaplan–Meier analysis)
was carried out in all cases. Figure 3 showed Kaplan–
Meier curves of Cygb, PI3K, p-Akt, IL-6, TNFα and
VEGF expression with overall survival in the entire case.
The parameters adversely affecting survival in all casesFigure 2 Immunohistochemical staining of IL-6, TNFα and VEGF
in low and high grade of glioma tissues. Low-grade gliomas
showed low expression of IL-6 (a), TNFα (b) and VEGF (c) positive
tumor cells in serial section. High expression of IL-6 (A), TNFα (B)
and VEGF (C) was shown in high-grade gliomas.
(magnification: ×400).were high histologic grade(p < 0.01), tumor recurrence
(p < 0.01), decreased Cygb expression(p < 0.01), increased
PI3K expression(p < 0.01), increased p-Akt expression (p
< 0.01) and increased VEGF expression (p = 0.023)
(Table 3). The overall survival is 42.9 ± 3.6 months for
all patients. The median survival time was 62.4 ± 4.8
months for patients overexpressing Cygb compared to
23.8 ± 3.1 months for patients with lower expression.
The median survival time for patients whose tumors
displayed overexpression of PI3K and p-Akt were 29.2 ±
4.2 months and 29.6 ± 4.3 months respectively. The cor-
responding figure for patients whose tumors presented
increased expression of IL-6, TNFα and VEGF were
40.1 ± 5.0 months, 44.2 ± 5.3 and 34.0 ± 3.6 months re-
spectively (Table 3).
Multivariate survival analysis (Cox regression model)
results including all parameters for the 88 patients, for
whom Cygb, PI3K, p-Akt, IL-6, TNFα, VEGF and CD34
staining results were available are presented in Table 4.
Only histological grade and Cygb expression appeared to
affect survival in all cases (Table 4). Other parameters,
such as age, gender, tumor recurrence, angiogenesis and
expression of PI3K, p-Akt, IL-6, TNFα and VEGF did
not show any association with the survival of the pa-
tients (Table 4).
Discussion
Cygb as a tumor suppressor gene has been demonstrated
in hepatocellular carcinoma, lung cancer and breast can-
cer [9-12]. Expression of Cygb has been reported in vari-
ous human tumors, including gliomas [5]. This study
showed that Cygb expression was found to inversely as-
sociate with higher histological grade in gliomas, and
lower expression of Cygb is closely related to a shorter
survival time of patients using either univariate or multi-
variate analysis. These results indicated that Cygb may
function not only as a tumor suppressor gene, which
was supported by previous studies, but also as a prog-
nostic factor. Previous studies have indicated that Cygb
Table 1 Correlation among Cygb, VEGF, PI3K, p-Akt, IL-6,TNFα expression and clinicopathological parameters of
patients with gliomas
Vareable Age (n = 88) Gender Histological grade Recurrence
Male
(n = 51)
Female
(n = 37)
Grade I
(n = 10)
Grade II
(n = 37)
Grade III
(n = 26)
Grade IV
(n = 15)
No (n = 31) Yes (n = 57)
Cygb expression
Median 39% 30% 52% 56.5% 66% 31.5% 14% 64% 22%
Range 10%-86% 11%-85% 10%-86% 20%-86% 12%-85% 18%-52% 10%-20% 25%-86% 10%-85%
p value 0.439▴ (r = -0.083) 0.031△ <0.01♦ <0.01△
PI3K expression
Median 20% 30% 15% 13% 11% 32.5% 38% 12% 27%
Range 3%-62% 3%-62% 3%-60% 3%-37% 3%-58% 7%-60% 24%-62% 3%-56% 5%-62%
p value 0.236▴ (r = 0.128) 0.055△ <0.01♦ <0.01△
p-Akt expression
Median 21% 27% 17% 15% 14% 31.5% 40% 15% 29%
Range 5%-67% 5%-62% 5%-67% 5%-38% 5%-60% 10%-57% 27%-67% 5%-58% 7%-67%
p value 0.135▴ (r = 0.161) 0.091△ <0.01♦ <0.01△
IL-6 expression
Median 35% 35% 35% 22.5% 27% 30% 46% 25% 40%
Range 4%-70% 5%-70% 4%-68% 4%-50% 7%-68% 8%-70% 12%-66% 4%-68% 5%-70%
p value 0.859▴ (r = 0.019) 0.472△ 0.019♦ 0.041△
TNFα expression
Median 30% 27% 33% 16% 22% 33% 47% 21% 35%
Range 3%-67% 3%-67% 4%-67% 4%-46% 3%-62% 3%-67% 10%-62% 3%-62% 3%-67%
p value 0.857▴ (r = -0.019) 0.543△ 0.010♦ 0.123△
VEGF expression
Median 56% 55% 58% 44% 32% 60.5% 67% 30% 61%
Range 10%-89% 10%-87% 11%-89% 11%-78% 10%-85% 10%-87% 12%-89% 10%-85% 10%-89%
p value 0.178▴ (r = 0.145) 0.337△ 0.027♦ 0.061△
▴ Results Spearman’s correlation coefficient. △ Results Mann–Whitney U test. ♦ Results Kruskal–Wallis ANOVA.
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tion and overexpression of IL-1, IL-6, VEGF, TNFα, and
TNFb mRNAs in cancer development in the liver and
lungs of mice exposed to N,N-diethylnitrosamine [14].
As we known, IL-1, IL-6, VEGF and TNFα are immuno-
suppressive cytokines. Immunosuppressive cytokines
and tumor biology are closely intertwined since in-
creased production of immunosuppressive cytokines in
cancer cells not only had a stimulating effect on tumor
cell growth and proliferation but also regarded as an in-
dispensable participation in tumor progression were
known to evade immune surveillance [30,31]. We postu-
lated that Cygb was likely to influence the prognosis of
glioma patients by effect on production of immunosup-
pressive cytokines and angiogenesis in gliomas.
In the present study, we found a direct relationship be-
tween Cygb expression level and tumor recurrence, in-
dependent of vascular density and angiogenic factor
expression. In particular, Grade I–II gliomas with lowerCygb expression were found more likely to recur during
the period of follow-up despite the low level of prolifera-
tive activity in this tumor. In the clinic, neither histo-
pathologic nor clinical data were currently taken as
reliable recurrence predictors for low-grade gliomas, es-
pecially for grade I tumors. Although the number of gli-
oma samples examined in this study was not sufficient
to allow us to draw a definite conclusion, our findings
indicated that Cygb expression level could be used as a
predictor for the recurrence of gliomas. There are some
histological features of gliomas associated with grade
and prognosis, such as the extent of vascular density
[32]. In our study, we found that low expression of Cygb
in glioma cells was closely associated with higher
microvessel density in tumor, which suggested Cygb
might contribute partly to angiogenesis of gliomas.
These results indicated that Cygb loss in tumor cells
might play an important role in tumor progression
through the induction of angiogenesis. In the present
Table 2 Spearman’s correlation coefficient between Cygb,
PI3K, p-Akt, IL-6, TNFα, VEGF expression and IMD value
Cygb PI3K p-Akt IL-6 TNFα VEGF
PI3K
r −0.728
p <0.0001
p-Akt
r −0.711 0.818
p <0.0001 <0.0001
IL-6
r −0.370 0.302 0.328
p <0.0001 0.004 0.002
TNFα
r −0.345 0.278 0.308 0.724
p 0.001 0.009 0.004 <0.0001
VEGF
r −0.378 0.395 0.406 0.714 0.702
p <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
IMD
r −0.514 0.396 0.426 0.710 0.691 0.605
p <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Figure 3 Kaplan-Meier curves estimates of overall survival according
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was significantly correlated with low expression of Cygb,
as well as higher histological grade and increased
neovascularization in tumors.
Previous study found that PI3K/Akt pathway is
deregulated in GBM [33] and activation of this pathway
has been shown to be associated with reduced patient
survival [34]. In our study, we found low level of Cygb
expression was associated with an increased Akt and
PI3K expression in gliomas. The increased levels of Akt
and PI3K correlated with a marked elevation of IL-6 and
TNFα. These data suggested that low expression of
Cygb, together with high expression of IL-6, TNFα, Akt
and PI3K might play an important role in the develop-
ment of glioma.
In this particular cohort, 62.2% (23 out of 37) of fe-
male patients was with low grade tumors while about
47% (24 out of 51) of male patients was diagnosed as
low grade tumors. The selection bias was found to cause
the gender difference in terms of histological grade.
Thus, the finding that low expression of Cygb was sig-
nificantly associated with female gender was most likely
because of difference in histological grade.
In further study, we will investigate the role of Cygb
expression by overexpressing via introducing exogenousto expression of Cygb, PI3K, p-Akt, IL-6, TNFα and VEGF.
Table 3 Kaplan–Meier analysis for overall survival rate of patients with gliomas
Characteristics Mean survival time ± SE 95% Confidence interval (months) P values
Age (years)
<41 49.8 ± 5.4 39.2-60.4 0.055
≥41 35.7 ± 4.5 26.8-44.5
Gender
Male 39.2 ± 4.6 30.1-48.2 0.086
Female 46.2 ±4.3 37.8-54.6
Histological grade
Low-grade (WHOI-II) 60.7 ±4.2 52.5-69.0 <0.01
High-grade (WHO III-IV) 17.3 ±1.7 14.0-20.7
Tumor recurrence
No 61.8 ±1.1 59.6-63.9 <0.01
Yes 33.1 ± 3.7 25.9-40.3
Cygb expression
Low expression (<39%) 23.8 ±3.1 17.8-29.8 <0.01
High expression (≥39%) 62.4 ±4.8 53.0-71.7
PI3K expression
Low expression (<20%) 56.5 ± 5.1 46.4-66.5 <0.01
High expression (≧%) 29.2 ± 4.2 20.9-37.5
p-Akt expression
Low expression (<21%) 55.4 ± 5.1 45.3-65.4 <0.01
High expression (≧20%) 29.6 ± 4.3 21.2-38.1
IL-6 expression
Low expression(<35%) 45.9 ± 5.2 35.7-56.2 0.157
High expression (≧35%) 40.1 ± 5.0 30.3-49.8
TNFα expression
Low expression (<30%) 62.9 ± 4.6 33.8-51.9 0.569
High expression (≧30%) 44.2 ± 5.3 33.7-54.6
VEGF expression
Low expression (<56%) 50.1 ± 5.2 39.9-60.4 0.023
High expression (≧56%) 34.0 ± 3.6 26.9-41.2
Table 4 Cox regression model for multivariate analyses of prognostic factor in gliomas
Variable Wald Hazard ratio 95% Confidence interval P value
Age (>41 vs <41) 0.678 0.722 0.333-1.567 0.410
Gender (male vs. female) 0.830 0.696 0.319-1.518 0.362
Histological grade (low-grade vs. high-grade) 14.358 15.320 3.734-62.857 <0.01
Tumor recurrence (no vs. yes) 3.142 6.383 0.822-49.563 0.076
Cygb expression (low vs. high) 5.254 0.235 0.068-0.811 0.022
PI3K expression (low vs. high) 0.808 3.161 0.275-38.859 0.369
p-Akt expression (low vs. high) 0.323 0.503 0.047-5.374 0.570
IL-6 expression (low vs. high) 2.137 2.730 0.710-10.493 0.144
TNFα expression (low vs. high) 1.818 0.390 0.099-1.532 0.178
VEGF expression (low vs. high) 1.119 0.560 0.191-1.641 0.290
Angiogenesis (IMD value) 0.375 1.016 0.966-1.068 0.540
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http://www.biomedcentral.com/1471-2407/13/247Cygb or silencing Cygb protein via siRNA in cultured
glioma cells. Moreover, we will try to develop animal
models of gliomas either by transgenic models or by
subcutaneous injection to charcterize the significance of
Cygb overexpression or inhibition.
Conclusion
In conclusion, the present data indicated prognostic sig-
nificance of Cygb in gliomas: correlation with PI3K, Akt,
IL-6, TNFα, VEGF, microvessel morphometry and survival
of patients with gliomas. Cygb loss may play an important
role in contributing to production of immunosuppressive
cytokines and angiogenesis in gliomas. Histological grade
and Cygb expression in tumors are independent predictors
for the prognosis of patients with gliomas. Moreover, Cygb
expression level may help determine whether aggressive
therapy is necessary, particularly for those gliomas with
lower WHO grades.
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